Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), PSCA inhibitors(Prostate stem cell antigen inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Neoplasms | Phase 1 | DE | 15 Apr 2019 | |
Kidney Neoplasms | Phase 1 | DE | 15 Apr 2019 | |
Kidney Neoplasms | Phase 1 | DE | 15 Apr 2019 | |
Kidney Neoplasms | Phase 1 | DE | AvenCell Europe GmbHStartup | 15 Apr 2019 |
Kidney Neoplasms | Phase 1 | DE | 15 Apr 2019 | |
Kidney Neoplasms | Phase 1 | DE | AvenCell Europe GmbHStartup | 15 Apr 2019 |
Non-Small Cell Lung Cancer | Phase 1 | DE | 15 Apr 2019 | |
Pancreatic Cancer | Phase 1 | DE | 15 Apr 2019 | |
Prostatic Cancer | Phase 1 | DE | 15 Apr 2019 | |
Prostatic Cancer | Phase 1 | DE | 15 Apr 2019 |